Annual Retained Earnings
-$742.15 M
-$70.80 M-10.55%
31 December 2023
Summary:
EyePoint Pharmaceuticals annual retained earnings is currently -$742.15 million, with the most recent change of -$70.80 million (-10.55%) on 31 December 2023. During the last 3 years, it has fallen by -$231.47 million (-45.33%). EYPT annual retained earnings is now -32058.16% below its all-time high of -$2.31 million, reached on 30 June 2001.EYPT Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
-$831.62 M
-$29.36 M-3.66%
30 September 2024
Summary:
EyePoint Pharmaceuticals quarterly retained earnings is currently -$831.62 million, with the most recent change of -$29.36 million (-3.66%) on 30 September 2024. Over the past year, it has dropped by -$103.57 million (-14.23%). EYPT quarterly retained earnings is now -12920.46% below its all-time high of -$6.39 million, reached on 30 June 2003.EYPT Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EYPT Retained Earnings Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -10.6% | -14.2% |
3 y3 years | -45.3% | -51.3% |
5 y5 years | -81.7% | -82.8% |
EYPT Retained Earnings High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -45.3% | at low | -51.3% | at low |
5 y | 5 years | -81.7% | at low | -82.8% | at low |
alltime | all time | <-9999.0% | at low | <-9999.0% | at low |
EyePoint Pharmaceuticals Retained Earnings History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | -$831.62 M(+3.7%) |
June 2024 | - | -$802.26 M(+4.0%) |
Mar 2024 | - | -$771.43 M(+3.9%) |
Dec 2023 | -$742.15 M(+10.5%) | -$742.15 M(+1.9%) |
Sept 2023 | - | -$728.05 M(+1.8%) |
June 2023 | - | -$715.43 M(+3.3%) |
Mar 2023 | - | -$692.51 M(+3.2%) |
Dec 2022 | -$671.35 M(+18.0%) | -$671.35 M(+6.9%) |
Sept 2022 | - | -$627.90 M(+3.0%) |
June 2022 | - | -$609.48 M(+3.3%) |
Mar 2022 | - | -$590.07 M(+3.7%) |
Dec 2021 | -$569.10 M(+11.4%) | -$569.10 M(+3.5%) |
Sept 2021 | - | -$549.66 M(+3.1%) |
June 2021 | - | -$532.97 M(+1.9%) |
Mar 2021 | - | -$522.96 M(+2.4%) |
Dec 2020 | -$510.68 M(+9.8%) | -$510.68 M(+3.1%) |
Sept 2020 | - | -$495.21 M(+0.8%) |
June 2020 | - | -$491.41 M(+2.7%) |
Mar 2020 | - | -$478.46 M(+2.8%) |
Dec 2019 | -$465.29 M(+13.9%) | -$465.29 M(+2.3%) |
Sept 2019 | - | -$454.88 M(+3.6%) |
June 2019 | - | -$439.23 M(+2.7%) |
Mar 2019 | - | -$427.73 M(+7.8%) |
Dec 2018 | -$408.49 M(+12.2%) | - |
Sept 2018 | - | -$396.90 M(+9.0%) |
June 2018 | -$363.99 M(+17.1%) | -$363.99 M(+10.4%) |
Mar 2018 | - | -$329.56 M(+2.2%) |
Dec 2017 | - | -$322.58 M(+1.8%) |
Sept 2017 | - | -$316.80 M(+1.9%) |
June 2017 | -$310.82 M(+6.4%) | -$310.82 M(+2.0%) |
Mar 2017 | - | -$304.58 M(+1.7%) |
Dec 2016 | - | -$299.44 M(+0.0%) |
Sept 2016 | - | -$299.38 M(+2.5%) |
June 2016 | -$292.21 M(+8.0%) | -$292.21 M(+2.2%) |
Mar 2016 | - | -$285.83 M(+1.8%) |
Dec 2015 | - | -$280.79 M(+1.9%) |
Sept 2015 | - | -$275.60 M(+1.8%) |
Date | Annual | Quarterly |
---|---|---|
June 2015 | -$270.67 M(-2.3%) | -$270.67 M(+1.9%) |
Mar 2015 | - | -$265.52 M(+1.9%) |
Dec 2014 | - | -$260.52 M(+1.6%) |
Sept 2014 | - | -$256.45 M(-7.4%) |
June 2014 | -$277.01 M(+5.1%) | -$277.01 M(+1.5%) |
Mar 2014 | - | -$273.05 M(+0.8%) |
Dec 2013 | - | -$270.86 M(+1.3%) |
Sept 2013 | - | -$267.35 M(+1.4%) |
June 2013 | -$263.66 M(+4.7%) | -$263.66 M(+1.5%) |
Mar 2013 | - | -$259.71 M(+1.1%) |
Dec 2012 | - | -$256.92 M(+1.0%) |
Sept 2012 | - | -$254.31 M(+1.0%) |
June 2012 | -$251.76 M(+10.9%) | -$251.76 M(+0.9%) |
Mar 2012 | - | -$249.50 M(+1.1%) |
Dec 2011 | - | -$246.81 M(+7.6%) |
Sept 2011 | - | -$229.35 M(+1.1%) |
June 2011 | -$226.92 M(+4.0%) | -$226.92 M(+0.1%) |
Mar 2011 | - | -$226.78 M(+2.4%) |
Sept 2010 | - | -$221.40 M(+1.4%) |
June 2010 | -$218.29 M(-3.9%) | -$218.29 M(-5.7%) |
Mar 2010 | - | -$231.37 M(+1.2%) |
Dec 2009 | - | -$228.66 M(+0.0%) |
Sept 2009 | - | -$228.64 M(+0.7%) |
June 2009 | -$227.05 M(+1.1%) | -$227.05 M(+0.2%) |
Mar 2009 | - | -$226.51 M(+0.3%) |
Dec 2008 | - | -$225.88 M(+0.4%) |
Sept 2008 | - | -$225.01 M(+0.2%) |
June 2008 | -$224.54 M(+50.8%) | -$224.54 M(+39.5%) |
Mar 2008 | - | -$160.96 M(+3.5%) |
Dec 2007 | - | -$155.46 M(+4.0%) |
Sept 2007 | - | -$149.44 M(+0.4%) |
June 2007 | -$148.87 M(+252.2%) | -$148.87 M(+19.5%) |
Dec 2006 | - | -$124.53 M(+194.6%) |
June 2006 | -$42.27 M(+93.5%) | -$42.27 M(+93.5%) |
June 2005 | -$21.84 M(+138.3%) | -$21.84 M(+138.3%) |
June 2004 | -$9.17 M(+43.5%) | -$9.17 M(+43.5%) |
June 2003 | -$6.39 M(+176.8%) | -$6.39 M |
June 2001 | -$2.31 M | - |
FAQ
- What is EyePoint Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual retained earnings year-on-year change?
- What is EyePoint Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly retained earnings year-on-year change?
What is EyePoint Pharmaceuticals annual retained earnings?
The current annual retained earnings of EYPT is -$742.15 M
What is the all time high annual retained earnings for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual retained earnings is -$2.31 M
What is EyePoint Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, EYPT annual retained earnings has changed by -$70.80 M (-10.55%)
What is EyePoint Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of EYPT is -$831.62 M
What is the all time high quarterly retained earnings for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly retained earnings is -$6.39 M
What is EyePoint Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, EYPT quarterly retained earnings has changed by -$103.57 M (-14.23%)